A Study of KL590586 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting 414 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Timeline

Start: 2021-09-15
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KL590586	Unknown	—	—

A Study of KL590586 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications